Jurickson Profar Suspended 162 Games for PEDs: Braves Impact & Appeal

ATLANTA – Jurickson Profar’s resurgence with the Atlanta Braves has been abruptly halted. Major League Baseball announced on Tuesday a 162-game suspension for the outfielder/designated hitter after testing positive for exogenous testosterone, a performance-enhancing substance. The suspension, which begins on Friday, effectively ends Profar’s 2026 season and raises serious questions about his future with the team.

This marks Profar’s second PED violation in as many years, and the second of his career. He was previously suspended for 80 games during the 2025 season after a positive test for human chorionic gonadotropin (hCG). As a repeat offender, Profar was not granted a stay of the suspension pending appeal, though the Players Association intends to file a grievance challenging the ruling, according to reports. The expedited appeal process will aim for a swift resolution, but the likelihood of overturning the ban is slim.

The Braves released a statement expressing their disappointment, stating, “We were incredibly disappointed to learn that Jurickson tested positive for a performance-enhancing substance and is in violation of MLB’s Drug Prevention and Treatment Program. Our players are consistently educated about the Program and the consequences if they are found to be in violation. The Atlanta Braves fully support the Program.”

Profar, 33, signed a three-year, $42 million contract with Atlanta prior to the 2025 season, hoping to solidify his career after years of inconsistency. He had a career year in 2024 with the San Diego Padres, earning his first All-Star selection. However, his time with the Braves has been marred by off-field issues and now, this significant suspension. He will forfeit his $15 million salary for the 2026 season, adding financial sting to the on-field loss.

The suspension leaves a considerable void in the Braves’ lineup. Profar was projected to be a key contributor, potentially hitting cleanup and serving as the team’s primary designated hitter. His absence complicates the team’s plans, particularly given recent injuries to starting pitchers Spencer Schwellenbach and Hurston Waldrep, both of whom underwent elbow surgery to address loose bodies and bone spurs. Schwellenbach is already on the 60-day injured list, and Waldrep is expected to join him.

Atlanta’s rotation now relies on Chris Sale, Spencer Strider, Reynaldo Lopez, and Grant Holmes as its core. Lopez is still working his way back from shoulder surgery, having made only one start in 2025. Holmes underwent a UCL tear repair last summer and rehabbed without surgery. The remaining rotation spots are filled by Bryce Elder, Joey Wentz, Didier Fuentes, and Jose Suarez, creating uncertainty as the season approaches.

The financial implications of Profar’s suspension are noteworthy. Beyond the forfeited salary, the Braves will too save approximately $3 million in luxury tax payments, bringing the total savings to $18 million. This newfound financial flexibility could allow the team to pursue additional pitching support or a veteran right-handed bat to bolster the offense. The team currently projects to be slightly above the $244 million luxury tax threshold.

Profar’s career trajectory has been anything but linear. Once considered one of the top prospects in baseball as a switch-hitting shortstop, his development was derailed by multiple shoulder injuries requiring surgery. He struggled to regain his form in the years following, bouncing between positions and teams. A stint with the Oakland Athletics proved underwhelming, and he later returned to the Padres, where he experienced a resurgence before signing with the Braves.

His 2025 season with Atlanta was a microcosm of his career – promising flashes interrupted by a suspension. He hit .245 with 14 home runs in 80 games before being sidelined. The 2026 season was meant to be a fresh start, a chance to prove his value and solidify his place in the Braves’ lineup. Instead, it will be remembered as another chapter in a career defined by unrealized potential and now, repeated violations of baseball’s drug policy.

The Braves have a roster of capable players, including Mike Yastrzemski, Michael Harris II, and Ronald Acuña Jr. In the outfield. However, Profar’s versatility and potential offensive contributions will be sorely missed. The team will need to rely on internal options and potentially explore external acquisitions to fill the void left by his suspension. Veterans like Lucas Giolito, Zack Littell, and Tyler Anderson remain available in free agency, offering potential solutions to the team’s pitching and hitting needs.

The Profar situation serves as a stark reminder of the ongoing battle against performance-enhancing drugs in baseball. While MLB has implemented stricter penalties and testing protocols, the issue continues to plague the sport. For the Braves, the suspension is a significant setback, but it also presents an opportunity to reassess their roster and explore new avenues to contend for a championship. The coming weeks will be crucial as the team navigates these challenges and prepares for the 2026 season.